The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive MAPK pathway activation

Tan, J. M., Tom, L. N., Jagirdar, K., Lambie, D., Schaider, H., Sturm, R. A., Soyer, H. P. and Stark, M. S. (2017) The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive MAPK pathway activation. British Journal of Dermatology, . doi:10.1111/bjd.15809


Author Tan, J. M.
Tom, L. N.
Jagirdar, K.
Lambie, D.
Schaider, H.
Sturm, R. A.
Soyer, H. P.
Stark, M. S.
Title The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive MAPK pathway activation
Formatted title
The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive MAPK pathway activation
Journal name British Journal of Dermatology   Check publisher's open access policy
ISSN 0007-0963
1365-2133
Publication date 2017-07-17
Sub-type Article (original research)
DOI 10.1111/bjd.15809
Open Access Status Not yet assessed
Total pages 19
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Language eng
Formatted abstract
Background: Acquired naevi can have unique dermoscopic patterns that correspond to distinct microanatomical growth patterns. Previous studies on acquired naevi stratified according to dermoscopic pattern, focused on the frequency of somatic BRAF mutations, whereas NRAS mutations remained to be elucidated.

Objectives: To investigate the BRAF and NRAS mutation prevalence and activation of the MAPK pathway in distinct dermoscopic subtypes of acquired naevi.

Methods: Common mutations present in BRAF and NRAS were assessed in 40 globular, reticular, and peripheral rim of globules (PG) subtypes of acquired naevi from 27 participants (19 male, 8 female; mean age 46.7 years) selected from 1261 eligible volunteers. Mutations were determined using the highly sensitive and quantitative QX200 droplet digital™ PCR (ddPCR) system.

Results: The BRAFV600E (c.1799T>A or c.1799_1800delTGinsA) and BRAFV600K mutations were detected in 85% (n=34/40) of naevi. All BRAF wild-type naevi (15%; n=6/40) harboured an NRAS codon 12/13 or 61 mutation. BRAF mutations were present in 92% (n=12/13) of globular and 100% (n=12/12) of PG naevi, whereas reticular naevi were 67% (n=10/15) BRAF and 33% (n=5/15) NRAS mutant (p=0.037).

Conclusions: We discovered that 100% of the assessed acquired naevi had either a BRAF or NRAS mutation. Using sensitive techniques capable of single-cell mutation detection, it is likely that all acquired naevi will be mutated for BRAF or NRAS. Since both of these mutations are prevalent in distinct dermoscopic naevus subsets, our study supports the role of the MAPK pathway in the development of benign melanocytic proliferations, indicating that additional genomic events besides somatic mutations in BRAF or NRAS are required for melanoma development.
Keyword BRAF
NRAS
Dermoscopy
Naevi
Globular
Reticular
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
UQ Diamantina Institute Publications
Admin Only - UQ Diamantina Institute
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 18 Jul 2017, 09:02:49 EST by Mitchell Stark on behalf of UQ Diamantina Institute